Search

Your search keyword '"Philippe, Bruno"' showing total 44 results
Start Over Author "Philippe, Bruno"
44 results on '"Philippe, Bruno"'

1. Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia: a post-hoc analysis of a randomized clinical trial

Author

Attal-Behar, Julie, Beaune, Sébastien, Thierry chinet, Cudennec, Tristan, de Laroche, Marine, de Thezy, Albane, Dumoulin, Jennifer, Dupont, Caroline, Fercot, Elise, Giraut, Violaine, Greffe, Ségolène, Grenet, Julie, Guyot, Caroline, Labrune, Sylvie, Lachatre, Marie, Moulias, Sophie, Naline, Charlotte, Pépin, Marion, Rouveix, Elisabeth, Sahut-D'izarn, Marine, Sefssafi, Abel, Teillet, Laurent, Bru, Jean-Pierre, Gaillat, Jacques, Gautier, Vincent, Janssen, Cécile, Pagani, Leonardo, Vitrat, Virginie, Abderrahmane, Malika, Camuset, Juliette, Legall, Catherine, Longuet-Flandres, Pascale, Menn, Anne-Marie, de Lastours, Victoire, Prevost, Gwenolée, Lecronier, Marie, Burdet, Charles, Derradji, Ouda, Escaut, Lelia, Hinglais, Etienne, Lebras, Philippe, Lefevre, Edouard, Noaillon, Mathilde, Rabier, Pauline, Raphaël, Maurice, Teicher, Elina, Verny, Christiane, Vittecoq, Daniel, Wyplosz, Benjamin, Ben Hayoun, Michèle, Brun-Vezinet, Françoise, Casalino, Enrique, Choquet, Christophe, Dombret, Marie-Christine, Duval, Xavier, Houhou, Nadhira, Joly, Véronique, Lescure, Xavier, Pogliaghi, Manuela, Rioux, Christophe, Yazdanpanah, Yazdan, Barros, Elsa, Begga, Belinda, Boukobza, Sébastien, Bouredji, Houria, Chouahi, Imad, Delacroix, Isabelle, Froissart, Antoine, Garrait, Valérie, Ngwem, Elsa, Phlippoteau, Catherine, Salehabadi, Sepehr, Toper, Cécile, Vinas, Florent, Amsilli, Marie, Epaulard, Olivier, Pavese, Patricia, Pierre, Isabelle, Stahl, Jean-Paul, Aulagnier, Jérôme, Celerier, Julie, Cojocariu, Roxana, Kahn, Jean-Emmanuel, Mathieu, Emmanuel, Rachline, Charlotte, Schoindre, Yoland, Sene, Thomas, Thierry, Christelle, Aparicio, Caroline, Delcey, Véronique, Lopes, Amanda, Pierre, Marjolaine Morgand, Sellier, Simoneau, Guy, Chakvetadze, Catherine, Diamantis, Sylvain, Gauthier, Arnaud, Jidar, Kaoutar, Jourdain, Béatrice, Boitiaux, Jean-Francois, Deschamps, Patrick, Devaud, Edouard, Philippe, Bruno, Calin, Ruxandra-Oana, Chroboczek, Tomasz, Davido, Benjamin, Deconinck, Laurène, de Truchis, Pierre, Lagrange, Aurore, Makhloufi, Sabrina, Matt, Morgan, Mellon, Guillaume, Senard, Olivia, Benhamou, Daniel, Chapuzet, Claire, Chauffrey, Laure, Etienne, Manuel, Joly, Luc-Marie, Obstoy, Bérengère, Salaun, Mathieu, Thiberville, Luc, Tillon, Julie, Bollens, Diane, Bottero, Julie, Campa, Pauline, Cosqueric, Gäelle, Lefebvre, Bénédicte, Ouazene, Zineb, Pacanowski, Jérôme, Pateron, Dominique, Valin, Nadia, Compain, Caroline, Cordel, Hugues, Doumenc, Benoit, Fois, Elena, Gambier, Nicolas, Khuong, Marie-Aude, Pasqualoni, Elisa, Poupard, Marie, Dinh, Aurélien, Duran, Clara, Ropers, Jacques, Bouchand, Frédérique, Calin, Ruxandra, Chinet, Thierry, Renaud, Bertrand, Claessens, Yann-Erick, Labarère, José, Bedos, Jean-Pierre, Aegerter, Philippe, and Crémieux, Anne-Claude

Published
2024
Full Text
View/download PDF

2. CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma

Author

Mal, Hervé, Le Guen, Pierre, Dupin, Clairelyne, Meurice, Jean Claude, Verdaguer, Marion, de Keizer, Joe, Delétage-Métreau, Céline, Le Mao, Raphael, Tromer, Cécile, Fajole, Gaëlle, Rayez, Mélanie, Raymond, Christel Saint, Gheerbrant, Hubert, Badatcheff, Anne, Person, Christine, Macey, Julie, Dermant, Xavier, Boitiaux, Jean-François, Gosset-Woimant, Marine, Metz-Favre, Carine, Degot, Tristan, Poulet, Claire, Popin, Elisabeth, Gamez, Anne Sophie, Boissin, Clément, Prevotat, Anne, Mangiapan, Gilles, Brouquières, Danielle, Le Floch, Hervé, Morisse-Pradier, Hélène, Sattler, Caroline, Muti, Daniela, Germaud, Patrick, Dirou, Stéphanie, Paris, Audrey, Melloni, Boris, Ballouhey, Julia, Bondeelle, Louise, Laurent, Lucie, Belleguic, Chantal, Kerjouan, Mallorie, Deslée, Gaëtan, Dury, Sandra, Bergot, Emmanuel, Magnier, Romain, Morel, Hugues, Lemaire, Bertrand, Tumino, Cécile, Sénéchal, Agathe, Choinier, Pascaline, Parrot, Antoine, Godet, Cendrine, Brun, Anne-Laure, Couturaud, Francis, Laurent, François, Frat, Jean-Pierre, Marchand-Adam, Sylvain, Gagnadoux, Frédéric, Blanchard, Elodie, Taillé, Camille, Philippe, Bruno, Hirschi, Sandrine, Andréjak, Claire, Bourdin, Arnaud, Chenivesse, Cécile, Dominique, Stéphane, Murris-Espin, Marlène, Rivière, Frédéric, Garcia, Gilles, Blanc, François-Xavier, Goupil, François, Bergeron, Anne, Flament, Thomas, Priou, Pascaline, Ragot, Stéphanie, and Cadranel, Jacques

Published
2024
Full Text
View/download PDF

3. CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma

Author

Godet, Cendrine, primary, Brun, Anne-Laure, additional, Couturaud, Francis, additional, Laurent, François, additional, Frat, Jean-Pierre, additional, Marchand-Adam, Sylvain, additional, Gagnadoux, Frédéric, additional, Blanchard, Elodie, additional, Taillé, Camille, additional, Philippe, Bruno, additional, Hirschi, Sandrine, additional, Andréjak, Claire, additional, Bourdin, Arnaud, additional, Chenivesse, Cécile, additional, Dominique, Stéphane, additional, Mangiapan, Gilles, additional, Murris-Espin, Marlène, additional, Rivière, Frédéric, additional, Garcia, Gilles, additional, Blanc, François-Xavier, additional, Goupil, François, additional, Bergeron, Anne, additional, Flament, Thomas, additional, Priou, Pascaline, additional, Mal, Hervé, additional, de Keizer, Joe, additional, Ragot, Stéphanie, additional, Cadranel, Jacques, additional, Le Guen, Pierre, additional, Dupin, Clairelyne, additional, Meurice, Jean Claude, additional, Verdaguer, Marion, additional, Delétage-Métreau, Céline, additional, Le Mao, Raphael, additional, Tromer, Cécile, additional, Fajole, Gaëlle, additional, Rayez, Mélanie, additional, Raymond, Christel Saint, additional, Gheerbrant, Hubert, additional, Badatcheff, Anne, additional, Person, Christine, additional, Macey, Julie, additional, Dermant, Xavier, additional, Boitiaux, Jean-François, additional, Gosset-Woimant, Marine, additional, Metz-Favre, Carine, additional, Degot, Tristan, additional, Poulet, Claire, additional, Popin, Elisabeth, additional, Gamez, Anne Sophie, additional, Boissin, Clément, additional, Prevotat, Anne, additional, Brouquières, Danielle, additional, Le Floch, Hervé, additional, Morisse-Pradier, Hélène, additional, Sattler, Caroline, additional, Muti, Daniela, additional, Germaud, Patrick, additional, Dirou, Stéphanie, additional, Paris, Audrey, additional, Melloni, Boris, additional, Ballouhey, Julia, additional, Bondeelle, Louise, additional, Laurent, Lucie, additional, Belleguic, Chantal, additional, Kerjouan, Mallorie, additional, Deslée, Gaëtan, additional, Dury, Sandra, additional, Bergot, Emmanuel, additional, Magnier, Romain, additional, Morel, Hugues, additional, Lemaire, Bertrand, additional, Tumino, Cécile, additional, Sénéchal, Agathe, additional, Choinier, Pascaline, additional, and Parrot, Antoine, additional

Published
2024
Full Text
View/download PDF

5. Zygomycosis in Solid Organ Transplant Recipients: A Prospective, Matched Case-Control Study to Assess Risks for Disease and Outcome

Author

Singh, Nina, Aguado, Jose M., Bonatti, Hugo, Forrest, Graeme, Gupta, Krishan L., Safdar, Nasia, John, George T., Pursell, Kenneth J., Muñoz, Patricia, Patel, Robin, Fortun, Jesus, Martin-Davila, Pilar, Philippe, Bruno, Philit, François, Tabah, Alexis, Terzi, Nicolas, Chatelet, Valérie, Kusne, Shimon, Clark, Nina, Blumberg, Emily, Julia, Marino Blanes, Humar, Abhi, Houston, Sally, Lass-Flörl, Cornelia, Johnson, Leonard, Dubberke, Erik R., Barron, Michelle A., and Lortholary, Olivier

Published
2009

6. Nebulised liposomal-amphotericin-B as maintenance therapy in ABPA: a randomised, multicentre, trial

Author

Godet, Cendrine, Couturaud, Francis, Marchand-Adam, Sylvain, Pison, Christophe, Gagnadoux, Frédéric, Blanchard, Elodie, Taillé, Camille, Philippe, Bruno, Hirschi, Sandrine, Andréjak, Claire, Bourdin, Arnaud, Chenivesse, Cécile, Dominique, Stéphane, Bassinet, Laurence, Murris-Espin, Marlène, Rivière, Frédéric, Garcia, Gilles, Caillaud, Denis, Blanc, François-Xavier, Goupil, François, Bergeron, Anne, Gondouin, Anne, Frat, Jean-Pierre, Flament, Thomas, Camara, Boubou, Priou, Pascaline, Brun, Anne-Laure, Laurent, François, Ragot, Stéphanie, Cadranel, Jacques, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience; Background In allergic bronchopulmonary aspergillosis (ABPA), prolonged nebulised antifungal treatment may be a strategy for maintaining remission. Methods We performed a randomised, single-blind, clinical trial in 30 centres. Patients with controlled ABPA after a 4-month attack treatment (corticosteroids and itraconazole) were randomly assigned to nebulised liposomal-amphotericin-B or placebo for 6 months. The primary outcome was occurrence of a first severe clinical exacerbation within 24 months following randomisation. Secondary outcomes included the median time-to-first severe clinical exacerbation, number of severe clinical exacerbations per patient, ABPA-related biological parameters. Results Among 174 enrolled patients with ABPA from March 2015 through July 2017, 139 were controlled after 4-month attack treatment and were randomised. The primary outcome occurred in 33 (50.8%) of 65 patients in nebulised liposomal-amphotericin-B group and 38 (51.3%) of 74 in placebo group (absolute difference −0.6%, 95% CI −16.8% to +15.6%, odds ratio 0.98, 95% CI 0.50 to 1.90; p=0.95). The median time-to-first severe clinical exacerbation was longer in liposomal-amphotericin-B group, 337 days (IQR, 168 to 476) versus 177 (64 to 288). At the end of maintenance therapy, total immunoglobulin-E and Aspergillus precipitins were significantly decreased in nebulised liposomal-amphotericin-B group. Conclusions In ABPA, maintenance therapy using nebulised liposomal-amphotericin-B did not reduce the risk of severe clinical exacerbation. The presence of some positive secondary outcomes creates clinical equipoise for further research.

Published
2021
Full Text
View/download PDF

8. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial

Author

Dinh, Aurélien, primary, Ropers, Jacques, additional, Duran, Clara, additional, Davido, Benjamin, additional, Deconinck, Laurène, additional, Matt, Morgan, additional, Senard, Olivia, additional, Lagrange, Aurore, additional, Makhloufi, Sabrina, additional, Mellon, Guillaume, additional, de Lastours, Victoire, additional, Bouchand, Frédérique, additional, Mathieu, Emmanuel, additional, Kahn, Jean-Emmanuel, additional, Rouveix, Elisabeth, additional, Grenet, Julie, additional, Dumoulin, Jennifer, additional, Chinet, Thierry, additional, Pépin, Marion, additional, Delcey, Véronique, additional, Diamantis, Sylvain, additional, Benhamou, Daniel, additional, Vitrat, Virginie, additional, Dombret, Marie-Christine, additional, Renaud, Bertrand, additional, Perronne, Christian, additional, Claessens, Yann-Erick, additional, Labarère, José, additional, Bedos, Jean-Pierre, additional, Aegerter, Philippe, additional, Crémieux, Anne-Claude, additional, ATTAL-BEHAR, Julie, additional, BEAUNE, Sébastien, additional, CHINET, Thierry, additional, CUDENNEC, Tristan, additional, DE LAROCHE, Marine, additional, DE THEZY, Albane, additional, DUMOULIN, Jennifer, additional, DUPONT, Caroline, additional, FERCOT, Elise, additional, GIRAUT, Violaine, additional, GREFFE, Ségolène, additional, GRENET, Julie, additional, GUYOT, Caroline, additional, KAHN, Jean-Emmanuel, additional, LABRUNE, Sylvie, additional, LACHATRE, Marie, additional, MOULIAS, Sophie, additional, NALINE, Charlotte, additional, PEPIN, Marion, additional, ROUVEIX, Elisabeth, additional, SAHUT-D'IZARN, Marine, additional, SEFSSAFI, Abel, additional, TEILLET, Laurent, additional, BRU, Jean-Pierre, additional, GAILLAT, Jacques, additional, GAUTIER, Vincent, additional, JANSSEN, Cécile, additional, PAGANI, Leonardo, additional, VITRAT, Virginie, additional, ABDERRAHMANE, Malika, additional, CAMUSET, Juliette, additional, LEGALL, Catherine, additional, LONGUET-FLANDRES, Pascale, additional, MENN, Anne-Marie, additional, DE LASTOURS, Victoire, additional, LECRONIER, Marie, additional, PREVOST, Gwenolée, additional, BURDET, Charles, additional, DERRADJI, Ouda, additional, ESCAUT, Lelia, additional, HINGLAIS, Etienne, additional, LEBRAS, Philippe, additional, LEFEVRE, Edouard, additional, NOAILLON, Mathilde, additional, RABIER, Pauline, additional, RAPHAEL, Maurice, additional, TEICHER, Elina, additional, VERNY, Christiane, additional, VITTECOQ, Daniel, additional, WYPLOSZ, Benjamin, additional, BEN HAYOUN, Michèle, additional, BRUN-VEZINET, Françoise, additional, CASALINO, Enrique, additional, CHOQUET, Christophe, additional, DOMBRET, Marie-Christine, additional, DUVAL, Xavier, additional, HOUHOU, Nadhira, additional, JOLY, Véronique, additional, LESCURE, Xavier, additional, POGLIAGHI, Manuela, additional, RIOUX, Christophe, additional, YAZDANPANAH, Yazdan, additional, BARROS, Elsa, additional, BEGGA, Belinda, additional, BOUKOBZA, Sébastien, additional, BOUREDJI, Houria, additional, CHOUAHI, Imad, additional, DELACROIX, Isabelle, additional, FROISSART, Antoine, additional, GARRAIT, Valérie, additional, NGWEM, Elsa, additional, PHLIPPOTEAU, Catherine, additional, SALEHABADI, Sepehr, additional, TOPER, Cécile, additional, VINAS, Florent, additional, AMSILLI, Marie, additional, EPAULARD, Olivier, additional, PAVESE, Patricia, additional, PIERRE, Isabelle, additional, STAHL, Jean-Paul, additional, AULAGNIER, Jérôme, additional, CELERIER, Julie, additional, COJOCARIU, Roxana, additional, MATHIEU, Emmanuel, additional, RACHLINE, Charlotte, additional, SCHOINDRE, Yoland, additional, SENE, Thomas, additional, THIERRY, Christelle, additional, APARICIO, Caroline, additional, DELCEY, Véronique, additional, LOPES, Amanda, additional, MORGAND, Marjolaine, additional, SELLIER, Pierre, additional, SIMONEAU, Guy, additional, CHAKVETADZE, Catherine, additional, DIAMANTIS, Sylvain, additional, GAUTHIER, Arnaud, additional, JIDAR, Kaoutar, additional, JOURDAIN, Béatrice, additional, BOITIAUX, Jean-Francois, additional, DESCHAMPS, Patrick, additional, DEVAUD, Edouard, additional, PHILIPPE, Bruno, additional, CALIN, Ruxandra-Oana, additional, CHROBOCZEK, Tomasz, additional, DAVIDO, Benjamin, additional, DECONINCK, Laurène, additional, DE TRUCHIS, Pierre, additional, LAGRANGE, Aurore, additional, MAKHLOUFI, Sabrina, additional, MATT, Morgan, additional, MELLON, Guillaume, additional, SENARD, Olivia, additional, BENHAMOU, Daniel, additional, CHAPUZET, Claire, additional, CHAUFFREY, Laure, additional, ETIENNE, Manuel, additional, JOLY, Luc-Marie, additional, OBSTOY, Bérengère, additional, SALAUN, Mathieu, additional, THIBERVILLE, Luc, additional, TILLON, Julie, additional, BOLLENS, Diane, additional, BOTTERO, Julie, additional, CAMPA, Pauline, additional, COSQUERIC, Gäelle, additional, LEFEBVRE, Bénédicte, additional, OUAZENE, Zineb, additional, PACANOWSKI, Jérôme, additional, PATERON, Dominique, additional, VALIN, Nadia, additional, COMPAIN, Caroline, additional, CORDEL, Hugues, additional, DOUMENC, Benoit, additional, FOIS, Elena, additional, GAMBIER, Nicolas, additional, KHUONG, Marie-Aude, additional, PASQUALONI, Elisa, additional, and POUPARD, Marie, additional

Published
2021
Full Text
View/download PDF

9. Ont collaboré à cet ouvrage

Author

Asselah, Tarik, primary, Bakchine, Serge, additional, Mouret, Sylvain Balester, additional, Batel, Philippe, additional, Bernard, Jean-Antoine, additional, Blétry, Olivier, additional, Boisaubert, Bernard, additional, Bordenave, Mathieu, additional, Bourdain, Frédéric, additional, Boyer, Nathalie, additional, Brézin, Antoine, additional, Briet, Marie, additional, Brissot, Pierre, additional, Brousse, Christine, additional, Cabane, Jean, additional, Casadevall, Nicole, additional, Chabolle, Frédéric, additional, Chapelle, Olga, additional, Chapron, Charles, additional, Cherin, Patrick, additional, Chopin, Nicolas, additional, Cordier, Bernard, additional, Crenn, Pascal, additional, Berthaud, Jocelyne Crnac, additional, Cudennec, Tristan, additional, Decroix, Jean-Pierre, additional, Delahousse, Michel, additional, Élalamy, Ismail, additional, Foubert, Luc, additional, Gardel, Bérénice, additional, Gepner, Patrick, additional, Girszyn, Nicolas, additional, Godeau, Bertrand, additional, Gompel, Anne, additional, Gourgon, René, additional, Grandpeix, Catherine, additional, Graveleau, Philippe, additional, Grimaldi, André, additional, Grivois, Jean-Philippe, additional, Grünfeld, Jean-Pierre, additional, Guiomard, Alain, additional, Hadoux, Mélissa, additional, Hanslik, Thomas, additional, Hatron, Pierre-Yves, additional, Hausser-Hauw, Chantal, additional, Hervé, Jean-Marie, additional, Houillier, Pascal, additional, Kahn, Jean-Emmanuel, additional, Kettaneh, Adrien, additional, Klein, André, additional, Krivitzky, Alain, additional, Laloum, Laurent, additional, Lebret, Thierry, additional, Lechowski, Laurent, additional, Leport, Jacques, additional, Lugagne, Pierre-Marie, additional, Malek-Chéhire, Nayla, additional, Marcellin, Patrick, additional, Marroun, Ibrahim, additional, Masquet, Christiane, additional, Mathieu, Emmanuel, additional, Matis, Richard, additional, Melchior, Jean-Claude, additional, Melchior, Yves, additional, Moraillon, Maud, additional, Moucari, Rami, additional, Ohresser, Martine, additional, Pedarriosse, Anne-Marie, additional, Philippe, Bruno, additional, Piette, Anne-Marie, additional, Poulain, Jean-Eudes, additional, Querleu, Denis, additional, Rafii, Arash, additional, Robain, Gilberte, additional, Rousset, Hugues, additional, Sananès, Michel, additional, Schaison, Monique, additional, Somogyi, Alexandre, additional, Somogyi-Demerjian, Nathalie, additional, Thomas, Michel, additional, Thomas, Olivier, additional, Tonnel, André-Bernard, additional, Touati, Michelle-Anne, additional, Toupet, Michel, additional, Tricot, Leila, additional, Trotoux, Jacques, additional, Varet, Bruno, additional, Vignes, Stéphane, additional, Vu, Patrick, additional, and Zucman, David, additional

Published
2009
Full Text
View/download PDF

16. Pleural ultrasonography, new standard for para pneumonic effusion? French multicentric prospective study. Preliminary report

Author

Garoute, Camille, primary, Rault, Isabelle, additional, Gosset-woimant, Marine, additional, Basille, Damien, additional, Philippe, Bruno, additional, Mangapian, Gilles, additional, Le Floch, Herve, additional, Laroumagne, Sophie, additional, Morel, Hughes, additional, Richard, Philippe, additional, Flament, Thomas, additional, Goupil, Francois, additional, D'halluin, Xavier, additional, Scheerperel, Arnaud, additional, Huet, Isabelle, additional, Ampere, Alexandre, additional, Lecuyer, Emmanuelle, additional, Suguenot, Remi, additional, Dayen, Charles, additional, Jounieaux, Vincent, additional, Douadi, Youcef, additional, and Drucbert, Melanie, additional

Published
2017
Full Text
View/download PDF

17. Erratum à « Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique » Rev. Mal. Respir. 30 (10) 879—902]

Author

Cottin, Vincent, Crestani, Bruno, Valeyre, Dominique, Wallaert, Benoît, Cadranel, Jacques, Dalphin, Jean Charles, Delaval, Philippe, Israël-Biet, Dominique, Kessler, Romain, Reynaud-Gaubert, Martine, Cordier, Jean-François, Aguilaniu, Bernard, Bouquillon, Benoit, Carré, Philippe, Danel, Claire, Faivre, Jean Baptiste, Ferretti, Gilbert, Just, Nicolas, Kouzan, Serge, Lebargy, François, Marchand Adam, Sylvain, Philippe, Bruno, Prevot, Grégoire, Stach, Bruno, Thivolet-Bejui, Françoise, Rétrovirus et Pathologie Comparée, Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Ecole Nationale Vétérinaire de Lyon (ENVL)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS), Centre de compétences pour les maladies pulmonaires rares, Clinique du Mail, Opened Mind Health and Associatesix, Polyclinique Montréal, Partenaires INRAE, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Albert Calmette, Hôpital Michallon, Centre Hospitalier Victor Provo, Centre Hospitalier Intercommunal, Hôpital Maison Blanche, Hôpital Bretonneau, Assistance Publique - Hôpitaux de Paris (AP-HP), Centre Hospitalier René Dubos [Pontoise], Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Cabinet médical, and Hospices Civils de Lyon (HCL)

Subjects
[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
Abstract

Une erreur s’est glissée dans l’orthographe du nom de l’auteur G. Ferretti.; National audience

Published
2014
Full Text
View/download PDF

18. CT Imaging Assessment of Response to Treatment in Chronic Pulmonary Aspergillosis

Author

Godet, Cendrine, primary, Laurent, François, additional, Bergeron, Anne, additional, Ingrand, Pierre, additional, Beigelman-Aubry, Catherine, additional, Camara, Boubou, additional, Cottin, Vincent, additional, Germaud, Patrick, additional, Philippe, Bruno, additional, Pison, Christophe, additional, Toper, Cécile, additional, Carette, Marie France, additional, Frat, Jean-Pierre, additional, Béraud, Guillaume, additional, Roblot, France, additional, Cadranel, Jacques, additional, Khalil, Antoine, additional, Blouin, Pascal, additional, and Godet, Cendrine, additional

Published
2016
Full Text
View/download PDF

19. Phenotyping chronic pulmonary aspergillosis by cluster analysis

Author

Godet, Cendrine, primary, Laurent, François, additional, Béraud, Guillaume, additional, Toper, Cécile, additional, Camara, Boubou, additional, Philippe, Bruno, additional, Germaud, Patrick, additional, Cottin, Vincent, additional, Beigelman-Aubry, Catherine, additional, Khalil, Antoine, additional, Blouin, Pascal, additional, Pouriel, Mathilde, additional, Roblot, France, additional, Bergeron, Anne, additional, and Cadranel, Jacques, additional

Published
2015
Full Text
View/download PDF

20. Computed tomography assessment of response to treatment in chronic pulmonary aspergillosis

Author

Godet, Cendrine, primary, Laurent, François, additional, Bergeron, Anne, additional, Begeilman, Catherine, additional, Pison, Christophe, additional, Cottin, Vincent, additional, Germaud, Patrick, additional, Philippe, Bruno, additional, Camara, Boubou, additional, Toper, Cécile, additional, Beraud, Guillaume, additional, Roblot, France, additional, and Cadranel, Jacques, additional

Published
2015
Full Text
View/download PDF

22. When should respiratory physicians consider lung transplantation for their patients ? Inscription criteria for the National Waiting List

Author

Philippe, Bruno, Dromer, Claire, Mornex, Jean-François, Velly, Jean-Francois, Stern, Marc, Service de pneumologie [Hôpital Foch], Hôpital Foch [Suresnes], CHU Bordeaux [Bordeaux], Rétrovirus et Pathologie Comparée (RPC), Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Ecole Nationale Vétérinaire de Lyon (ENVL), Hospices Civils de Lyon (HCL), and ProdInra, Migration

Subjects
[SDV] Life Sciences [q-bio], SARCOÏDOSE, CONNECTIVITÉS, [SDV]Life Sciences [q-bio], LISTE D’ATTENTE, TRANSPLANTATION PULMONAIRE, HYPERTENSION ARTÉRIELLE PULMONAIRE, MUCOVISCIDOSE
Abstract

Introduction Placing a patient on the national lung transplant waiting list remains a difficult matter, and is more a question of timing than selection of the candidate according to disease-specific criteria. Back-ground The listing criteria for cystic fibrosis are FEV1 less than 30% of the predicted value, hypoxaemia with a PaO2 less than 55 mm Hg and hypercapnia with a PaCO2 over 50 mm Hg. The rate of decline of FEV1, increasing antibiotic requirements and life threatening complications can all accelerate the listing procedure. For primary pulmonary hypertension the criteria are persistent dyspnoea, NYHA grade III or IVA, despite epoprostenol treatment and a 6 minute walk test of less than 250 metres. Sarcoidosis, lymphangioleiomyomatosis, histiocytosis X and connective tissue diseases are rare indications for which the listing criteria are similar to those for the more usual respiratory diseases. View points Further therapeutic advances, increased numbers of available organs and changes in the allocation rules will necessitate periodical updates of these selection and listing criteria. Conclusion The optimal time for placing lung transplantation patients who have been referred early in the course of their disease on the waiting list will be determined by clinical experience and individual patient follow-up., Introduction L’inscription d’un patient sur la liste nationale d’attente de transplantation pulmonaire reste une question délicate non tant par les critères de sélection des candidats que par le choix du moment. État des connaissances Les critères d’inscription pour la mucoviscidose sont définis par un VEMS inférieur à 30 % de la valeur théorique, une hypoxémie inférieure à 55 mmHg et une hypercapnie supérieure à 50 mmHg. La vitesse du déclin du VEMS, l’antibiodépendance et une complication mettant en jeu le pronostic vital accélèrent l’inscription. Les contre-indications restent relatives. Ceux de l’hypertension artérielle pulmonaire sont une dyspnée stade III ou IV NHYA persistante après traitement par époprosténol et un périmètre de marche inférieur à 250 mètres. La sarcoïdose, la lymphangioleïomyomatose, l’histiocytose et les connectivites sont des indications rares dont les critères d’inscription rejoignent ceux des autres pathologies respiratoires plus classiques. Perspectives Les innovations thérapeutiques, l’augmentation des greffons disponibles et les changements des règles d’allocations des greffons devront faire réévaluer les critères de sélection des patients et d’inscription sur la liste d’attente. Conclusion L’expérience clinique et le suivi de chaque patient restent des éléments primordiaux pour juger du moment opportun d’inscription sur liste de transplantation de patients adressés suffisamment tôt aux centres spécialisés.

Published
2009

23. Expression of Calcineurin Activity after Lung Transplantation: A 2-Year Follow-Up

Author

Sanquer, Sylvia, primary, Amrein, Catherine, additional, Grenet, Dominique, additional, Guillemain, Romain, additional, Philippe, Bruno, additional, Boussaud, Veronique, additional, Herry, Laurence, additional, Lena, Celine, additional, Diouf, Alphonsine, additional, Paunet, Michelle, additional, Billaud, Eliane M., additional, Loriaux, Françoise, additional, Jais, Jean-Philippe, additional, Barouki, Robert, additional, and Stern, Marc, additional

Published
2013
Full Text
View/download PDF

26. In vivobiofilm composition ofAspergillus fumigatus

Author

Loussert, Céline, primary, Schmitt, Christine, additional, Prevost, Marie-Christine, additional, Balloy, Viviane, additional, Fadel, Elie, additional, Philippe, Bruno, additional, Kauffmann-Lacroix, Catherine, additional, Latgé, Jean Paul, additional, and Beauvais, Anne, additional

Published
2010
Full Text
View/download PDF

27. Relative Impact of Human Leukocyte Antigen Mismatching and Graft Ischemic Time After Lung Transplantation

Author

Brugière, Olivier, primary, Thabut, Gabriel, additional, Suberbielle, Caroline, additional, Reynaud-Gaubert, Martine, additional, Thomas, Pascal, additional, Pison, Christophe, additional, Saint Raymond, Christel, additional, Mornex, Jean-François, additional, Bertocchi, Michèle, additional, Dromer, Claire, additional, Velly, Jean-François, additional, Stern, Marc, additional, Philippe, Bruno, additional, Dauriat, Gaëlle, additional, Biondi, Giuseppina, additional, Castier, Yves, additional, and Fournier, Michel, additional

Published
2008
Full Text
View/download PDF

28. Telemetric Monitoring of Pulmonary Function After Allogeneic Hematopoietic Stem Cell Transplantation

Author

Guihot, Amélie, primary, Becquemin, Marie-Hélène, additional, Couderc, Louis-Jean, additional, Randrianarivelo, Odile, additional, Rivaud, Elisabeth, additional, Philippe, Bruno, additional, Sutton, Laurent, additional, Neveu, Hélène, additional, Tanguy, Marie-Laure, additional, Vernant, Jean-Paul, additional, and Dhédin, Nathalie, additional

Published
2007
Full Text
View/download PDF

29. Home Telemetric System for Pulmonary Function Surveillance: A Useful Procedure for Detection of Late-Onset Noninfectious Pulmonary Complications (LONIPC) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Author

Guihot, Amélie, primary, Becquemin, Marie-Hélène, additional, Couderc, Louis-Jean, additional, Randrianarivelo, Odile, additional, Rivaud, Elisabeth, additional, Philippe, Bruno, additional, Neveu, Hélène, additional, Vernant, Jean-Paul, additional, and Dhedin, Nathalie, additional

Published
2005
Full Text
View/download PDF

32. Catalases of Aspergillus fumigatus

Author

Paris, Sophie, primary, Wysong, Deborah, additional, Debeaupuis, Jean-Paul, additional, Shibuya, Kazutoshi, additional, Philippe, Bruno, additional, Diamond, Richard D., additional, and Latgé, Jean-Paul, additional

Published
2003
Full Text
View/download PDF

33. Conidial Hydrophobins ofAspergillus fumigatus

Author

Paris, Sophie, primary, Debeaupuis, Jean-Paul, additional, Crameri, Reto, additional, Carey, Marilyn, additional, Charlès, Franck, additional, Prévost, Marie Christine, additional, Schmitt, Christine, additional, Philippe, Bruno, additional, and Latgé, Jean Paul, additional

Published
2003
Full Text
View/download PDF

34. Collaborateurs

Author

Aubert, Lucie, Balester-Mouret, Sylvain, Batel, Philippe, Bernard, Jean-Antoine, Beurrier, Frédéric, Bletry, Olivier, Boisaubert, Bernard, Bordenave, Mathieu, Bourdain, Frederic, Brezin, Antoine, Brissot, Pierre, Brousse, Christine, Cabane, Jean, Carrabin, Nicolas, Casadevall, Nicole, Chabolle, Frédéric, Chapelle, Olga, Cherin, Patrick, Chopin, Nicolas, Cordier, Bernard, Cudennec, Tristan, Crenn, Pascal, Crnac, Jocelyne, Decroix, Jean-Pierre, Delahousse, Michel, Elalamy, Ismaïl, Eugene, Claude, Fagnen-Sylvaire, Marie-Christine, Faure, Christelle, Ferraioli, Domenicco, Foubert, Luc, Gardel, Bérénice, Gepner, Patrick, Girszyn, Nicolas, Godeau, Bertrand, Gompel, Anne, Grandpeix, Catherine, Graveleau, Philippe, Grimaldi, André, Grünfeld, Jean-Pierre, Guiomard, Alain, Hadoux, Mélissa, Hanachi, Mouna, Hanslik, Thomas, Hatron, Pierre-Yves, Hauser haw, Chantal, Herve, Jean-Marie, Houillier, Pascal, Kahn, Jean-Emmanuel, Kayser, N., Kettaneh, Adrien, Klein, André, Krivitzky, Alain, Laloum, Laurent, Lebret, Thierry, Lechowski, Laurent, Leport, Jacques, Lugagne-Delpon, Pierre-Marie, Malek Chehire, Nayla, Marcellin, Patrick, Marroun, Ibrahim, Mathieu, Emmanuel, Matis, Richard, Meeus, Pierre, Melchior, Jean-Claude, Melchior, Yves, Ohresser, Martine, Pedariosse, Anne-Marie, Philippe, Bruno, Piette, Anne-Marie, Poulain, Jean-Eudes, Ringuenet, Damien, Robain, Gilberte, Rousset, Hugues, Rousset-Jablonski, Christine, Sananes, Michel, Schaison, Monique, Sohier, Julie, Somogyi, Alexandre, Somogyi-Demerjian, Nathalie, Thomas, Michel, Thomas, Olivier, Tonnel, André-Bernard, Touati, Michelle-Anne, Toupet, Michel, Tricot, Leila, Trotoux, Jacques, Varet, Bruno, Vignes, Stéphane, Zucman, David, Briet, Marie, Chapron, Charles, Gourgon, René<ce:sup loc='post">†</ce:sup>, Grivois, Jean-Philippe, Moraillon, Maud, Querleu, Denis, Raffi, Arash, and Vu, Patrick

Published
2014
Full Text
View/download PDF

37. In vivo biofilm composition of Aspergillus fumigatus.

Author

Loussert, Céline, Schmitt, Christine, Prevost, Marie-Christine, Balloy, Viviane, Fadel, Elie, Philippe, Bruno, Kauffmann-Lacroix, Catherine, Latgé, Jean Paul, and Beauvais, Anne

Subjects
ASPERGILLUS fumigatus, BIOFILMS, EXTRACELLULAR matrix, CONNECTIVE tissues, PREVENTIVE medicine
Abstract

The in vivo composition of the mycelial extracellular matrix (ECM) of Aspergillus fumigatus during host invasion is reported here for the first time. A new galactosaminogalactan and the galactomannan were the major polysaccharides of the in vivo ECM. The composition of the ECM in vivo varied with the aspergillosis pathologies. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

38. Detection of AspergillusGalactomannan Antigenemia To Determine Biological and Clinical Implications of Beta-Lactam Treatments

Author

Bart-Delabesse, Emmanuelle, Basile, Maria, Al Jijakli, Ahmad, Souville, Didier, Gay, Fre´de´rick, Philippe, Bruno, Bossi, Philippe, Danis, Martin, Vernant, Jean-Paul, and Datry, Annick

Abstract

ABSTRACTDetection of Aspergillusgalactomannan (GM) in serum with the Platelia Aspergillusenzyme immunoassay (EIA) is useful for diagnosing invasive aspergillosis. From May 2003 to November 2004, 65 patients who did not develop aspergillosis had at least two positive sera while receiving a beta-lactam treatment (GM index [GMI], =0.5). Of the 69 treatment episodes scored, 41 consisted of a beta-lactam other than piperacillin-tazobactam (n= 29), namely, amoxicillin-clavulanate (n= 25), amoxicillin (n= 10), ampicillin (n= 3), or phenoxymethylpenicillin (n= 2). In all cases, antigenemia became negative 24 h to 120 h upon stopping the antibiotic. Monitoring of 35 patients, including 26 with hematological malignancies, revealed three antigenemia kinetic patterns: each was observed with any drug regimen and consisted of a persistent GMI of >2.0 (65.7%), >0.5, and =1.5 (25.7%) or a variable GMI (14.3%) from the onset of antibiotic therapy. All available drug batches given to 26 patients cross-reacted with the EIA. Galactomannan titration in batches failed to predict the GM titers in the five patients studied at cumulative doses of ampicillin or amoxicillin-clavulanate, regardless of the time lapse between serum sampling and infusion period. Our results show that beta-lactams other than piperacillin-tazobactam may lead to false presumption of aspergillosis. The resulting kinetic patterns of GM antigenemia are variable, and sampling serum prior to the next beta-lactam dose may not decrease GMI below the threshold. Consequently, testing of suspected antibiotic batches remains the only indicator of possible false EIA positivity.

Published
2005
Full Text
View/download PDF

39. Differential Expression of the Aspergillus fumigatus pksPGene Detected In Vitro and In Vivo with Green Fluorescent Protein

Author

Langfelder, Kim, Philippe, Bruno, Jahn, Bernhard, Latgé, Jean-Paul, and Brakhage, Axel A.

Abstract

ABSTRACTAspergillus fumigatusis an important pathogen of immunocompromised hosts, causing pneumonia and invasive disseminated disease with high mortality. To be able to analyze the expression of putative virulence-associated genes of A. fumigatus, the use of the enhanced green fluorescent protein (EGFP) as a reporter was established. Two 5′ sequences, containing the putative promoters of thepyrGgene, encoding orotidine-5′-phosphate decarboxylase, and the pksPgene, encoding a polyketide synthase involved in both pigment biosynthesis and virulence ofA. fumigatus, were fused with the egfpgene. The PpksP-egfpconstruct was integrated via homologous recombination into the genomicpksPlocus. EGFP production was analyzed by fluorescence spectrometry, Western blot analysis, and fluorescence microscopy. Differential gene expression in A. fumigatuswas observed. Fluorescence derived from the PYRG-EGFP fusion protein was detected during all developmental stages of the fungus, i.e., during germination, during vegetative growth, in conidiophores, and weakly in conidia. In addition, it was also detected in germinating conidia when isolated from the lungs of immunocompromised mice. By contrast, PKSP-EGFP-derived fluorescence was not found in hyphae or stalks of conidiophores but was found in phialides and conidia in vitro when the fungus was grown under standard conditions, indicating a developmentally controlled expression of the gene. Interestingly,pksP-egfpexpression was also detected in hyphae of germinating conidia isolated from the lungs of immunocompromised mice. This finding indicates that thepksPgene can also be expressed in hyphae under certain conditions and, furthermore, that the pksPgene might also contribute to invasive growth of the fungus.

Published
2001
Full Text
View/download PDF

41. Conidial Hydrophobins of Aspergillus furnigatus.

Author

Paris, Sophie, Debeaupuis, Jean-Paul, Crameri, Reto, Carey, Marilyn, Charlès, Franck, Prévost, Marie Christine, Schmitt, Christine, Philippe, Bruno, and Latgé, Jean Paul

Subjects
*CONIDIA, *ASPERGILLUS fumigatus
Abstract

Discusses the conidial hydrophobins of aspergillus fumigatus. Role of RodBp, a 14-kDa protein encoded by RODB gene, in the structure of the conidial cell wall; Sensitivity of rodletless mutant to killing by alveolar macrophages; Involvement of the rodlet structure in the resistance of the host cells.

Published
2003
Full Text
View/download PDF

42. Ont collaboré à cet ouvrage

Author

Asselah, Tarik, Bakchine, Serge, Mouret, Sylvain Balester, Batel, Philippe, Bernard, Jean-Antoine, Blétry, Olivier, Boisaubert, Bernard, Bordenave, Mathieu, Bourdain, Frédéric, Boyer, Nathalie, Brézin, Antoine, Briet, Marie, Brissot, Pierre, Brousse, Christine, Cabane, Jean, Casadevall, Nicole, Chabolle, Frédéric, Chapelle, Olga, Chapron, Charles, Cherin, Patrick, Chopin, Nicolas, Cordier, Bernard, Crenn, Pascal, Berthaud, Jocelyne Crnac, Cudennec, Tristan, Decroix, Jean-Pierre, Delahousse, Michel, Élalamy, Ismail, Foubert, Luc, Gardel, Bérénice, Gepner, Patrick, Girszyn, Nicolas, Godeau, Bertrand, Gompel, Anne, Gourgon, René, Grandpeix, Catherine, Graveleau, Philippe, Grimaldi, André, Grivois, Jean-Philippe, Grünfeld, Jean-Pierre, Guiomard, Alain, Hadoux, Mélissa, Hanslik, Thomas, Hatron, Pierre-Yves, Hausser-Hauw, Chantal, Hervé, Jean-Marie, Houillier, Pascal, Kahn, Jean-Emmanuel, Kettaneh, Adrien, Klein, André, Krivitzky, Alain, Laloum, Laurent, Lebret, Thierry, Lechowski, Laurent, Leport, Jacques, Lugagne, Pierre-Marie, Malek-Chéhire, Nayla, Marcellin, Patrick, Marroun, Ibrahim, Masquet, Christiane, Mathieu, Emmanuel, Matis, Richard, Melchior, Jean-Claude, Melchior, Yves, Moraillon, Maud, Moucari, Rami, Ohresser, Martine, Pedarriosse, Anne-Marie, Philippe, Bruno, Piette, Anne-Marie, Poulain, Jean-Eudes, Querleu, Denis, Rafii, Arash, Robain, Gilberte, Rousset, Hugues, Sananès, Michel, Schaison, Monique, Somogyi, Alexandre, Somogyi-Demerjian, Nathalie, Thomas, Michel, Thomas, Olivier, Tonnel, André-Bernard, Touati, Michelle-Anne, Toupet, Michel, Tricot, Leila, Trotoux, Jacques, Varet, Bruno, Vignes, Stéphane, Vu, Patrick, and Zucman, David

Full Text
View/download PDF

43. Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial.

Author

Godet C, Couturaud F, Marchand-Adam S, Pison C, Gagnadoux F, Blanchard E, Taillé C, Philippe B, Hirschi S, Andréjak C, Bourdin A, Chenivesse C, Dominique S, Bassinet L, Murris-Espin M, Rivière F, Garcia G, Caillaud D, Blanc FX, Goupil F, Bergeron A, Gondouin A, Frat JP, Flament T, Camara B, Priou P, Brun AL, Laurent F, Ragot S, Cadranel J, Godet C, Couturaud F, Cadranel J, Frat JP, Brun AL, Laurent F, Marchand-Adam S, Pison C, Gagnadoux F, Blanchard E, Taillé C, Philippe B, Hirschi S, Andréjak C, Chenivesse C, Dominique S, Bassinet L, Murris-Espin M, Rivière F, Garcia G, Caillaud D, Blanc FX, Goupil F, Gondouin A, Flament T, Camara B, Priou P, and Ragot S

Subjects
Amphotericin B adverse effects, Antifungal Agents therapeutic use, Aspergillus, Humans, Single-Blind Method, Aspergillosis, Allergic Bronchopulmonary drug therapy
Abstract

Background: In allergic bronchopulmonary aspergillosis (ABPA), prolonged nebulised antifungal treatment may be a strategy for maintaining remission., Methods: We performed a randomised, single-blind, clinical trial in 30 centres. Patients with controlled ABPA after 4-month attack treatment (corticosteroids and itraconazole) were randomly assigned to nebulised liposomal amphotericin-B or placebo for 6 months. The primary outcome was occurrence of a first severe clinical exacerbation within 24 months following randomisation. Secondary outcomes included the median time to first severe clinical exacerbation, number of severe clinical exacerbations per patient, ABPA-related biological parameters., Results: Among 174 enrolled patients with ABPA from March 2015 through July 2017, 139 were controlled after 4-month attack treatment and were randomised. The primary outcome occurred in 33 (50.8%) out of 65 patients in the nebulised liposomal amphotericin-B group and 38 (51.3%) out of 74 in the placebo group (absolute difference -0.6%, 95% CI -16.8- +15.6%; OR 0.98, 95% CI 0.50-1.90; p=0.95). The median (interquartile range) time to first severe clinical exacerbation was longer in the liposomal amphotericin-B group: 337 days (168-476 days) versus 177 days (64-288 days). At the end of maintenance therapy, total immunoglobulin-E and Aspergillus precipitins were significantly decreased in the nebulised liposomal amphotericin-B group., Conclusions: In ABPA, maintenance therapy using nebulised liposomal amphotericin-B did not reduce the risk of severe clinical exacerbation. The presence of some positive secondary outcomes creates clinical equipoise for further research., Competing Interests: Conflict of interest: C. Godet reports having received speaker fees, travel support from Pfizer, MSD; fees for board memberships from SOS Oxygène and Pulmatrix; grant support from Ohre Pharma, Pfizer, MSD, SOS Oxygène, ISIS Medical and AstraZeneca. Conflict of interest: F. Couturaud reports having received research grant support from Bristol-Myers Squibb/Pfizer and fees for board memberships or symposia from Bayer, Bristol-Myers Squibb/Pfizer, Merck Sharp & Dohme and AstraZeneca, and having received travel support from Bayer, Bristol-Myers Squibb/Pfizer, Leo Pharma, Merck Sharp & Dohme and Actelion. Conflict of interest: S. Marchand-Adam reports having received consultancy for board membership, consultancy or speaker fees and travel support from AstraZeneca, Boehringer Ingelheim, Novartis and Roche. Conflict of interest: C. Pison reports having received, outside of the submitted work, consultancy for board membership, consultancy or speaker fees, travel support from AGIR à Dom, Chiesi, Boehringer Ingelheim, GSK, SOS Oxygène, AstraZeneca and Novartis. Conflict of interest: F. Gagnadoux reports having received grants and personal fees from Resmed; personal fees and non-financial support from Boehringer Ingelheim, Nyxoah, Sefam; personal fees from Actelion, Cidelec, Novartis, and non-financial support from Asten, unrelated to the submitted work. Conflict of interest: E. Blanchard reports having received consultancy or speaker fees, travel support from Pfizer, MSD, Novartis, Gilead, Roche, Boehringer Ingelheim, SOS Oxygene and ISIS Medical. Conflict of interest: C. Taillé reports having received consulting or advisory fees from Sanofi, GSK, AstraZeneca, Novartis and Chiesi, and research grants from Sanofi and GSK, outside the submitted work. Conflict of interest: B. Philippe reports having received speaker fees, travel support from Chiesi, Novartis and Oxyvie. Conflict of interest: S. Hirschi reports having received research grant support from CSL Behring and Adiral, and fees for board membership from Boehringer Ingelheim and Roche. Conflict of interest: C. Andréjak reports having received fees for board memberships or symposia and travel support from GSK, AstraZeneca, Zambon and Insmed. Conflict of interest: A. Bourdin reports having received grants from AstraZeneca, Boehringer Ingelheim, Cephalon/TEVA, GlaxoSmithKline, Novartis and Sanofi-Regeneron; has provided consultancy for Actelion, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MedinCell, Merck, Novartis, Roche and Sanofi-Regeneron; and has acted as an investigator or co-investigator for trials sponsored by Actelion, AstraZeneca, Boehringer Ingelheim, Chiesi, Galapagos, GlaxoSmithKline, Merck, Novartis, Roche, Sanofi-Regeneron and Vertex. Conflict of interest: C. Chenivesse reports having received grants from AstraZeneca and Santelys outside the submitted work, personal fees from ALK-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKlein, Novartis, Sanofi-Regeneron and TEVA outside the submitted work and congress support from ALK-Abello, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pierre Fabre, Pfizer, Roche and TEVA. Conflict of interest: S. Dominique reports having received consultancy for board membership, speaker fees, travel support from Roche, Chiesi, Boehringer Ingelheim, AstraZeneca, Novartis and Actelion, outside the submitted work. Conflict of interest: L. Bassinet has nothing to disclose. Conflict of interest: M. Murris-Espin reports having received consultancy for board membership or speaker fees, or travel support, from Insmed, MSD, Pfizer, Asten, LVL, Vertex, Vivisol and Zambon. Conflict of interest: F. Rivière reports having received consultancy fees from Roche and Boehringer Ingelheim. Conflict of interest: G. Garcia reports having received grants from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi-Regeneron and Chiesi; has provided consultancy for AstraZeneca, GlaxoSmithKline, Novartis and Sanofi-Regeneron; and has acted as an investigator or co-investigator for trials sponsored by AstraZeneca, GlaxoSmithKline and Sanofi-Regeneron. Conflict of interest: D. Caillaud reports having received consultancy or speaker fees, travel support from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Menarini and Novartis. Conflict of interest: F-X. Blanc has nothing to disclose. Conflict of interest: F. Goupil reports having received travel support from Aliseo/Asten Santé, GSK, Chiesi, Novartis and Actelion. Conflict of interest: A. Bergeron reports having received consultancy or speaker fees, from Pfizer, Gilead, MSD, AstraZeneca and Takeda, and grants from SOS Oxygene. Conflict of interest: A. Gondouin reports having received consultancy or speaker fees, or travel support from Roche, Boehringer Ingelheim, Vitalaire, Actelion, LFB, GSK and Pfizer. Conflict of interest: J-P. Frat reports having received grants from the French Ministry of Health, outside the submitted work; grants, personal fees and non-financial support from Fisher & Paykel HealthCare, outside the submitted work; personal fees and non-financial support from SOS Oxygène, outside the submitted work. Conflict of interest: T. Flament has nothing to disclose. Conflict of interest: B. Camara reports having received outside of the submitted work, consultancy for speaker fees, travel supports from AGIR à Dom. Conflict of interest: P. Priou received travel support from Asten Santé. Conflict of interest: A-L. Brun has nothing to disclose. Conflict of interest: F. Laurent reports having received consultancy for board membership, consultancy or speaker fees, travel support from Bayer, Roche, Chiesi, Boehringer Ingelheim, SOS Oxygène, AstraZeneca, Basilea, Novartis and Actelion. Conflict of interest: S. Ragot has nothing to disclose. Conflict of interest: J. Cadranel reports having received speaker fees from MSD and Pfizer., (Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.)

Published
2022
Full Text
View/download PDF

44. Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines.

Author

Cottin V, Crestani B, Valeyre D, Wallaert B, Cadranel J, Dalphin JC, Delaval P, Israel-Biet D, Kessler R, Reynaud-Gaubert M, Aguilaniu B, Bouquillon B, Carré P, Danel C, Faivre JB, Ferretti G, Just N, Kouzan S, Lebargy F, Marchand-Adam S, Philippe B, Prévot G, Stach B, Thivolet-Béjui F, and Cordier JF

Subjects
Consensus, Diagnostic Imaging standards, Evidence-Based Medicine standards, France epidemiology, Humans, Idiopathic Pulmonary Fibrosis epidemiology, Predictive Value of Tests, Risk Factors, Treatment Outcome, Idiopathic Pulmonary Fibrosis diagnosis, Idiopathic Pulmonary Fibrosis therapy, Pulmonary Medicine standards
Abstract

Idiopathic pulmonary fibrosis (IPF) is the most frequent chronic idiopathic interstitial pneumonia in adults. The management of rare diseases in France has been organised by a national plan for rare diseases, which endorsed a network of expert centres for rare diseases throughout France. This article is an overview of the executive summary of the French guidelines for the management of IPF, an initiative that emanated from the French National Reference Centre and the Network of Regional Competence Centres for Rare Lung Diseases. This review aims at providing pulmonologists with a document that: 1) combines the current available evidence; 2) reviews practical modalities of diagnosis and management of IPF; and 3) is adapted to everyday medical practice. The French practical guidelines result from the combined efforts of a coordination committee, a writing committee and a multidisciplinary review panel, following recommendations from the Haute Autorité de Santé. All recommendations included in this article received at least 90% agreement by the reviewing panel. Herein, we summarise the main conclusions and practical recommendations of the French guidelines., (©ERS 2014.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results